AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00987311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1- Dairy drink containing probiotics A
Description: 1- Dairy drink containing probiotics A
Study NCT00987311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2- Dairy drink containing probiotics B
Description: 2- Dairy drink containing probiotics B
Study NCT00987311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 3- Dairy drink without probiotics (control)
Description: 3- Dairy drink without probiotics (control)
Study NCT00171171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study NCT03222687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
Study NCT03222687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
Study NCT00640965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-VPA
Description: DP-VPA dose escalation to 900mg, then continued for 8 weeks
Study NCT00640965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DP-VPA Placebo
Description: Matching Placebo to Active, dose escalation, then continued for 8 weeks
Study NCT04030572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: 0.1 mg tabs, one by mouth daily at bedtime for one week
Study NCT04151433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).
Description: cf. different arms
Study NCT01009008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Activated Controlled Expansion Device
Description: Patient activated controlled expansion for post-mastectomy breast reconstruction
Study NCT02898896 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: Additional 21 ml of blood will be collected
Study NCT01944124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
Study NCT01944124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Prescription
Description: An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
Study NCT01944124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
Study NCT00835250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal hybrid NOTES cholecystectomy
Description: Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
Study NCT00835250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Extirpation of the gallbladder by a surgical procedure
Study NCT00835250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Extirpation of the gallbladder by a surgical procedure
Study NCT03409783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENSO Device
Description: An active ENSO device that delivers neuromodulation therapy.
Study NCT03409783 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Device
Study NCT03425617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
Study NCT03425617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO via Respimat® single dose
Study NCT02150655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules
Study NCT02150655 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02064907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Orally Disintegrating Tablets
Description: Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
Study NCT02064907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Capsules
Description: Dexlansoprazole delayed-release capsules
Study NCT01234545 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
Study NCT00905255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00905255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT03039556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Daily Steps
Description: Complete normal daily ambulation for one week
Study NCT03039556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-Reduction
Description: Reduce daily ambulation to fewer than 1000 steps per day for two weeks
Study NCT03039556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to Normal Daily Steps
Description: Increase daily ambulation to 100% of normal daily step-count for two weeks
Study NCT02506322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEKT - Cognitive-Behavioral-Emotional
Description: This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management
Study NCT02506322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FEST - Clinical Supportive Educational
Description: This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
Study NCT01795989 — intervention group
Intervention type: DEVICE
Intervention: 1.5T MRI Elbow Coil
Description: Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
Study NCT03149484 — intervention group
Intervention type: DEVICE
Intervention: Personal remote microphone (RM) system
Description: Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
Study NCT03149484 — intervention group
Intervention type: OTHER
Intervention: Subjective Questionnaire
Description: These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
Study NCT03357016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training programs
Description: High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
Study NCT01110356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
Study NCT03982381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Active comparator
Study NCT03982381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Experimental treatment
Study NCT04513015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant diet
Description: The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed.
Study NCT04513015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal dietetic scheme
Description: Isocaloric, normolipidic diet for age and sex
Study NCT03265808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic human mesenchymal stem cells (allo-hMSCs)
Description: Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
Study NCT03265808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
Study NCT04178876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ethanol sclerotherapy
Description: Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
Study NCT04178876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping technique
Description: Endometrioma laparoscopic cystectomy
Study NCT03140709 — intervention group
Intervention type: DRUG
Intervention: Oxytocin
Description: Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr
Study NCT02350868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT0E028
Description: The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
Study NCT02370173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTSD wavelength-1 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning.
Study NCT02370173 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PTSD wavelength-2 bright light
Description: 6 weeks daily light exposure, 30 minutes per morning.
Study NCT02695316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group Discussion in native Language
Description: Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
Study NCT02695316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group Discussion
Description: Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
Study NCT02695316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: One-to-one Interview
Description: One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
Study NCT02695316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective Quantitative Analysis
Description: Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
Study NCT00966706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given systemically
Study NCT02553993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii Fit(30 Mins)
Description: Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
Study NCT02553993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback(30 Mins)
Description: Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
Study NCT00966706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given systemically
Study NCT02553993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional weight-shifting(30 Mins)
Description: Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
Study NCT03378921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
Study NCT03378921 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
Study NCT02679300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise group
Study NCT01110356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
Study NCT03804853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitiation
Description: This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
Study NCT02679300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise group (control group)
Study NCT02507531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeXsys Embolization System
Description: Woven metallic mesh placed in aneurysm fundus
Study NCT02658253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: 2.56 µg of GLA content
Study NCT01261299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon-14-labeled carboplatin
Description: Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
Study NCT03699722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Activities
Description: Format:Video; discussion; information handouts; facilitated referral
Study NCT03699722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Format: Information handouts
Study NCT03743571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
Study NCT03743571 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
Study NCT03743571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure therapy
Description: participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
Study NCT03743571 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exposure therapy
Description: participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
Study NCT04721431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric assessment
Description: MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
Study NCT01347905 — intervention group
Intervention type: OTHER
Intervention: Stable-isotope techniques
Description: Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
Study NCT00397982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00397982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00397982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT00397982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection
Study NCT03026712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real dual tDCS + Robotic Arm Therapy
Description: Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks.